By Colin Kellaher
Xilio Therapeutics shares took flight in premarket trading Wednesday after the clinical-stage biotechnology company formed a potentially lucrative collaboration with AbbVie that includes an equity investment at a rich premium.
Xilio, which had a market capitalization of around $30 million based on Tuesday's closing price of 65.7 cents, said AbbVie is investing $10 million at $2.30 a share and will also make an upfront payment of $42 million in cash as part of the deal.
Shares of the Waltham, Mass., company were recently up 113% to $1.40 in premarket trading.
Xilio said it is also eligible to receive up to about $2.1 billion in additional payments, including up to $305 million in program nomination fees, preclinical development option extension fees and option fees, and up to $1.8 billion in development, regulatory and sales-based milestones.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 12, 2025 08:26 ET (13:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.